FDA approves nivolumab for completely resected stage IIB/C melanoma
The treatment of patients with melanoma is undergoing a paradigm shift. In October 2023, the FDA approved nivolumab (Opdivo; Bristol Myers Squibb) for patients 12 years and older with completely resected stage IIB/C melanoma. 1 This recent approval is considered a groundbreaking development for patients with advanced melanoma.
Читать дальше...